公开(公告)号：US09580409B2

公开(公告)日：2017-02-28

申请号：US14352294

申请日：2012-11-07

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Scott Malcolm ,  Carrie Bowen ,  Laurence Melnick ,  Linghong Xie

IPC: C07D403/04 ,  C07D401/14 ,  C07D403/14 ,  C07D487/04 ,  C07D487/14 ,  C07D498/04 ,  C07D471/04 ,  C07D405/14 ,  C07D487/10 ,  C07D491/10 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/501 ,  A61K31/551 ,  A61K31/553

CPC classification number: C07D403/04 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/501 ,  A61K31/551 ,  A61K31/553 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/10 ,  C07D487/14 ,  C07D491/10 ,  C07D498/04

Abstract: Provided herein are compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as pain, neurological disorders, psychiatric disorders, and neuromuscular disorders. Compounds provided herein modulate the activity of opioid receptor (e.g., μ-opioid receptor) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

Abstract translation: 本文提供的化合物及其合成方法。 本文提供的化合物可用于治疗，预防和/或治疗各种疾病，例如疼痛，神经障碍，精神疾病和神经肌肉疾病。 本文提供的化合物调节中枢神经系统或周围的阿片受体（例如，μ-阿片受体）的活性。 本文还提供了含有化合物及其使用方法的药物制剂。

公开(公告)号：US09505751B2

公开(公告)日：2016-11-29

申请号：US14409866

申请日：2013-06-19

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： John Emmerson Campbell ,  Phillip G. Jones ,  Scott Malcolm

IPC: A61K31/4985 ,  C07D241/38 ,  C07D487/04 ,  C07D471/04 ,  A61K31/437 ,  A61K31/4709 ,  C07D519/00

CPC classification number: C07D519/00 ,  A61K31/437 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/4985 ,  C07D471/04 ,  C07D487/04

Abstract: Provided herein are substituted triazolopyrazine phosphodiesterase inhibitors, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.

Abstract translation: 本文提供了可用于治疗例如中枢神经系统和代谢疾病和病症的取代三唑并吡嗪磷酸二酯酶抑制剂及其药物组合物。

公开(公告)号：US20150322090A1

公开(公告)日：2015-11-12

申请号：US14409866

申请日：2013-06-19

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： John Emmerson Campbell ,  Phillip G. Jones ,  Scott Malcolm

IPC: C07D519/00 ,  C07D487/04 ,  C07D471/04 ,  A61K31/4709 ,  A61K31/4985 ,  A61K31/437

CPC classification number: C07D519/00 ,  A61K31/437 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/4985 ,  C07D471/04 ,  C07D487/04

Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.